Splash Beverage Group, Inc.

EDVA Healthcare Biotechnology

Splash Beverage Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $73,100.00, down 98.2% from fiscal 2024.

Revenue
−99.6%
EPS
+95.6%
Free cash flow
−95.7%
Total debt
−100.0%

Quarter to June 2026, against a year earlier

0.19 0.02 +11.76%
Market cap
$1.9M
P/E
0.0×
Fwd P/E
−0.4×
Dividend yield
—
F-score
3/9
Altman Z
−331.47
Beneish M
−101.16
Dividend safety
n/a

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 1.92
Revenue ttm 0.66
Net income ttm (17.28)
Free cash flow ttm (5.47)
Net debt Q (0.24)
Valuation
P/E 0.00
Forward P/E (0.44) (negative: loss-making)
Price / sales 0.88
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 0.05 (below 1: weak)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (8.69)
Growth
Revenue growth Q −99.57% (below 0%: shrinking)
Operating income growth Q −33.65% (below 0%: shrinking)
EPS, this year +11.43%
EPS, next year A −6.45% (below 0%: weak)
Revenue, next year A +24,359.64% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +12.64%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

P/S against its own 10 years 6.00%
10-year low 10-year high
EV/Sales against its own 10 years 4.87%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 0 0 0 0
Receivables 1 0 0 0
Inventory 2 0 0 0
Other — — — —
4 2 1 1
2023 2024 2025 Q'26
Payables 4 4 5 4
ST’ Debt 0 0 — —
Other — — 0 0
15 19 16 17

Compound Annual Growth %

10y 5y 3y
Sales (22.18%) (49.83%) (84.07%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

EPS $

Mar Jun Sep Dec Year
’26 (1.88) (0.79) — — —
’25 (7.88) (17.88) (18.04) (5.84) (47.88)
’24 (16.00) (17.60) (14.45) (22.52) (70.72)
’23 (15.96) (20.80) (20.80) (22.40) (78.40)
’22 (25.60) (25.60) (22.40) (18.41) (92.80)
’21 (26.36) (38.40) (64.00) (36.11) (161.60)
’20 (12.53) (3.15) (17.13) (214.68) (247.48)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 0 — — — —
’25 0 — — 0 0
’24 2 1 1 1 4
’23 6 5 5 3 19
’22 4 4 5 5 18
’21 2 3 3 3 11
’20 0 0 1 1 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 (1) (1) (2) (1) (5)
’24 (1) (2) (3) (1) (7)
’23 (4) (2) (2) (2) (10)
’22 (4) (3) (4) (3) (14)
’21 (4) (4) (4) (3) (15)
’20 (1) (1) (2) (17) (21)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 (1) (1) (2) (1) (5)
’24 (1) (2) (3) (1) (7)
’23 (4) (2) (2) (2) (10)
’22 (4) (3) (4) (3) (14)
’21 (4) (4) (4) (3) (15)
’20 (1) (1) (3) (17) (21)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1 1 1 0 2 11 18 19 4 0 1 (25.3%) 18 — — +24,359.6%
Gross margin, % 52.10 50.81 53.77 (1,103.43) 15.81 34.62 32.72 29.54 (2.88) 23.12 (120.66) (29.0) pt
EBT 0 0 0 (5) (20) (29) (22) (21) (18) (24) (17) +99.4%
EBT margin, % (4.82) (16.47) 5.21 (25,175.00) (851.62) (259.33) (119.64) (111.42) (423.78) (33,309.58) 0.00 (33,304.8) pt
Net income 0 0 0 (5) (29) (29) (22) (21) (24) (25) (17) +100.2%
Per share, $
Per share, $ Revenue 15.46 12.72 18.39 0.08 19.85 62.66 77.40 71.05 12.42 0.13 0.00 (41.0%)
Earnings (0.75) (2.09) 0.96 (20.01) (247.48) (161.60) (92.80) (78.40) (70.72) (47.88) (26.55) +58.8%
Cash flow 0.49 (0.25) 0.88 (10.36) (184.45) (84.24) (60.22) (38.41) (21.83) (8.85) (1.79) n/m
Capex (0.80) (0.60) (0.95) (0.05) (0.79) 0.00 (0.44) (0.05) (0.01) 0.00 0.00 n/m
Free cash flow (0.31) (0.85) (0.07) (10.40) (185.23) (84.24) (60.66) (38.46) (21.84) (8.85) (1.79) +45.4%
Book value 0.61 (1.04) (0.04) (38.01) (80.68) 49.13 39.89 (21.13) (55.69) (28.10) (5.14) n/m
Shares, m 0 0 0 0 0 0 0 0 0 1 1 +26.5%
Valuation, ×
Valuation, × P/E 255.43 255.43 255.43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 76.6
P/S 13.31 13.31 13.31 321.66 28.30 2.98 1.76 1.20 2.07 0.92 0.88 39.9
P/B 0.00 0.00 0.00 0.00 0.00 3.80 3.41 0.00 0.00 0.00 0.00 0.7
EV/Sales 13.32 13.32 13.32 335.21 29.01 2.67 1.66 1.21 2.59 0.87 0.82 41.3
EV/FCF (3,353.17) (3,353.17) (3,353.17) (40.41) (3.11) (1.98) (2.10) (2.24) (1.47) (0.30) (0.10) (1,011.1)
Cash, $m
Cash, $m Operating cash flow 0 0 0 (3) (21) (15) (14) (10) (7) (5) (5) n/m
Capex 0 0 0 0 0 — 0 0 0 — 0 (29.4%)
Free cash flow 0 0 0 (3) (21) (15) (14) (10) (7) (5) (5) +83.9%
Balance, $m
Balance, $m Working capital 0 0 0 (10) (3) 2 6 (11) (17) (16) (16) n/m
Net debt 0 0 0 4 2 (3) (2) 0 2 0 0 +30.4%
Shareholders’ equity 0 0 0 (10) (9) 9 9 (6) (19) (15) (16) n/m
Returns, %
Returns, % ROA (16.40) (49.47) 21.01 (1,013.36) (583.34) (226.86) (128.76) (154.42) (375.36) (1,399.60) (158.63) (1,383.2) pt
ROIC (220.07) 0.00 1,042.19 0.00 0.00 (337.71) (180.05) 0.00 0.00 0.00 0.00 +220.1 pt
ROE (255.50) 888.55 (180.42) 105.25 300.15 12,167.87 (238.42) (1,130.21) 196.01 153.62 525.95 +409.1 pt
People
People Employees 10 9 9 9 — 21 40 32 21 3 — (12.5%)
Revenue/emp, $m 0.10 0.10 0.15 0.00 0.00 0.54 0.45 0.59 0.20 0.02 — (14.6%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026

Splash Beverage Group, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SLXN Silexion Therapeutics Corp $2.2M — (loss-making) — — n/m −16.63% (below 0%: shrinking) — 0.00% Compare
BRTX Biorestorative Therapies, Inc. $2.1M — (loss-making) — (loss-making) −7.20% (below 0%: shrinking) n/m −35.26% (below 0%: shrinking) 68.10% (14,593.53%) Compare
SILO Silo Pharma, Inc. $2.1M — (loss-making) 18.4× 0.00% n/m +39.17% (above 0%: growing) (15.00%) 0.00% Compare
PPBT Purple Biotech Ltd. Sponsored ADR $2.0M — (loss-making) — (loss-making) — n/m −62.10% (below 0%: shrinking) 0.00% 0.00% Compare
REVB Revelation Biosciences, Inc. $2.0M — (loss-making) — — n/m −35.29% (below 0%: shrinking) 0.00% 0.00% Compare
ENLV Enlivex Ltd. $2.0M 0.0× — — n/m +35.94% (above 0%: growing) 0.00% 0.00% Compare
EDVA Splash Beverage Group, Inc. $1.9M — (loss-making) — (loss-making) −99.57% (below 0%: shrinking) n/m −95.72% (below 0%: shrinking) 42.86% 0.00%
GNPX GENPREX $1.7M — (loss-making) — — n/m −32.98% (below 0%: shrinking) 0.00% 0.00% Compare
PPCB Propanc Biopharma Inc $1.7M — (loss-making) — — −99.64% (below 0%: shrinking) −1,637.42% (below 0%: shrinking) — 0.00% Compare
Median of peers $2.0M — — — — −34.12% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 5 October 2026

Ownership

Directors and executive officers, together 8.80%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Splash Beverage Group, Inc. (EDVA) Latest News

6 Mar

Impact 4 · · just-drinks.com

26 Nov

Impact 4 · · just-drinks.com

11 Nov

10 Nov

Impact 3 · · NewMediaWireJust DrinksMT NewswiresSimply Wall St.MT NewswiresMT NewswiresMT NewswiresFood Dive
stockrow.com/EDVA · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com